tiprankstipranks
Blurbs

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Spruce Biosciences (SPRB), Equillium (EQ) and Cogent Biosciences (COGT)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Spruce Biosciences (SPRBResearch Report), Equillium (EQResearch Report) and Cogent Biosciences (COGTResearch Report).

Spruce Biosciences (SPRB)

In a report released yesterday, Joseph Schwartz from Leerink Partners maintained a Hold rating on Spruce Biosciences, with a price target of $3.00. The company’s shares closed last Wednesday at $1.86, close to its 52-week low of $1.81.

According to TipRanks.com, Schwartz has 0 stars on 0-5 stars ranking scale with an average return of -5.9% and a 32.5% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Mereo Biopharma Group Plc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Spruce Biosciences with a $9.67 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Equillium (EQ)

Leerink Partners analyst Thomas Smith initiated coverage with a Buy rating on Equillium yesterday. The company’s shares closed last Wednesday at $3.33, close to its 52-week low of $3.26.

According to TipRanks.com, Smith has 0 stars on 0-5 stars ranking scale with an average return of -19.2% and a 25.7% success rate. Smith covers the Healthcare sector, focusing on stocks such as Connect Biopharma Holdings, Madrigal Pharmaceuticals, and Prometheus Biosciences.

Currently, the analyst consensus on Equillium is a Strong Buy with an average price target of $12.00.

Cogent Biosciences (COGT)

In a report released yesterday, Christopher Liu from Leerink Partners maintained a Buy rating on Cogent Biosciences, with a price target of $14.00. The company’s shares closed last Wednesday at $5.46, close to its 52-week low of $5.15.

According to TipRanks.com, Liu has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -25.3% and a 15.0% success rate. Liu covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Monte Rosa Therapeutics, and Nurix Therapeutics.

Currently, the analyst consensus on Cogent Biosciences is a Strong Buy with an average price target of $22.50, a 306.9% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $22.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SPRB:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More